Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Guo J, Yu Z, Sun D, Zou Y, Liu Y, Huang L.
Mol Cancer. 2021 Jan 6;20(1):10. doi: 10.1186/s12943-020-01297-0.
PMID:33407548
Malignant pleural mesothelioma.
Ho L, Sugarbaker DJ, Skarin AT.
Cancer Treat Res. 2001;105:327-73. doi: 10.1007/978-1-4615-1589-0_13.
PMID:11224994
Therapeutic Vaccines for Cancer Immunotherapy.
Wang J, Mamuti M, Wang H.
ACS Biomater Sci Eng. 2020 Nov 9;6(11):6036-6052. doi: 10.1021/acsbiomaterials.0c01201. Epub 2020 Oct 23.
PMID:33449675
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.
Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V.
Mol Cancer. 2023 Oct 3;22(1):160. doi: 10.1186/s12943-023-01849-0.
PMID:37784179
A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
Yi K, Kong H, Zheng C, Zhuo C, Jin Y, Zhong Q, Mintz RL, Ju E, Wang H, Lv S, Lao YH, Tao Y, Li M.
Biomaterials. 2023 Nov;302:122349. doi: 10.1016/j.biomaterials.2023.122349. Epub 2023 Oct 6.
PMID:37844429
Nanoparticle-Based Combination Therapy for Ovarian Cancer.
Wu Y, Yang Y, Lv X, Gao M, Gong X, Yao Q, Liu Y.
Int J Nanomedicine. 2023 Apr 12;18:1965-1987. doi: 10.2147/IJN.S394383. eCollection 2023.
PMID:37077941
Intratumoral Immunotherapy for Early-stage Solid Tumors.
Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R.
Clin Cancer Res. 2020 Jul 1;26(13):3091-3099. doi: 10.1158/1078-0432.CCR-19-3642. Epub 2020 Feb 18.